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Mucopolysaccharidoses (MPS) are inherited metabolic disorders from the group of lysosomal storage dis-
eases (LSD). They arise from mutations causing dysfunction of one of enzymes involved in degradation of
glycosaminoglycans (GAGs) in lysosomes. Impaired degradation of these compounds results in their
accumulation in cells and dysfunction of most tissues and organs of patients. If heparan sulfate (HS) is
the sole or one of stored GAGs, brain functions are also affected. However, despite the fact that products
of incomplete degradation of the same chemical, HS, are accumulated in brains of patients suffering from
Hurler disease (MPS type I), Hunter disease (MPS type II), Sanﬁlippo disease (MPS type III) and Sly disease
(MPS type VII), and obvious deterioration of brain functions occur in these patients, their behavior is con-
siderably different between various types of MPS. Here we asked the question about biochemical reasons
of these differences. We performed theoretical analysis of products of incomplete HS degradation that
accumulate in tissues of patients diagnosed for these diseases. A correlation between chemical structures
of incompletely degraded HS and behaviors of patients suffering from particular MPS types was found.
We propose a hypothesis that particular chemical moieties occurring at the ends of incompletely
degraded HS molecules may determine characteristic behavioral disturbances, perhaps due to chemical
reactions interfering with functions of neurons in the brain. A possible experimental testing of this
hypothesis is also proposed. If the hypothesis is true, it might shed some new light on biochemical mech-
anisms of behavioral problems occurring not only in MPS but also in some other diseases.
 2010 Elsevier Ltd. All rights reserved.Introduction
Mucopolysaccharidoses (MPS) are inherited metabolic diseases,
from the group of lysosomal storage disorders (LSD), that occur
panethnically with cumulative frequencies of all their types of
about 1 per 40.000–50.000 live births [1]. These diseases are
caused by mutations in genes coding for enzymes involved in deg-
radation of glycosaminoglycans (GAGs) (formerly called muco-
polysaccharides). Their impaired hydrolysis leads to continuous
accumulation and storage of these compounds in cells of patients,
which results in a damage of the affected tissues, including the
heart, respiratory system, bones, joints and central nervous system
(CNS). MPS are usually fatal diseases (especially neuronopathic
forms of MPS), with average expected life span of one or two dec-ll rights reserved.
: +48 58 523 5501.
e˛grzyn).ades, though patients with milder forms can survive into adult-
hood [1].
On the basis of the nature of lacking or defective enzyme and
the kind(s) of stored GAG(s), 11 types and subtypes of MPS are dis-
tinguished (Table 1). Neuronopathic forms of MPS are found in 7
out of 11 types and subtypes, and dysfunctions of CNS correlate
with storage of heparan sulfate (HS), which together with
dermatan sulfate (DS) and keratan sulfate (KS) is one of main GAGs
(Table 1). Since MPS are progressive diseases, due to continuous
accumulation of GAGs, patients deteriorate continuously in the
course of these disorders, which reﬂects also cognitive abilities
and behavior of patients suffering from the neuronopathic forms.
Although prediction of severity and clinical progression of MPS is
very difﬁcult, even if biochemical and genetic data are available
[2], recent studies suggested that consideration of two or more bio-
chemical parameters may give signiﬁcantly better results in
assessment of MPS patients than attempting to make conclusion
based on a single biomarker [3].
Table 1
Mucopolysaccharidoses (MPS), stored GAGs, deﬁcient enzymes and neurological symptoms.
MPS type (syndrome name) Main GAGs
stored in cellsa
Deﬁcient enzyme Neurological symptoms
MPS I (Hurler disease - MPS I-H, Scheie disease – MPS I-S,
Hurler-Scheie disease – MPS I-H/S)
DS, HS a-L-iduronidase Severe (in the MPS I-H clinical subtype), very mild to mild
(in MPS I-H/S) or none (in MPS I-S)
MPS II (Hunter disease) DS, HS Iduronate sulfatase Severe or mild (rarely none)
MPS IIIA (Sanﬁlippo disease subtype A) HS Heparan N-sulfatase Severe
MPS IIIB (Sanﬁlippo disease subtype B) HS a-N-actylglucosaminidase Severe
MPS IIIC (Sanﬁlippo disease subtype C) HS Acetyl-CoA:a-
glycosaminide
acetyltransferase
Severe
MPS IIID (Sanﬁlippo disease subtype D) HS N-acetylglucosamine 6-
sulfatase
Severe
MPS IVA (Morquio disease subtype A) KS N-acetylgalactosaminide 6-
sulfatase
None
MPS IVB (Morquio disease subtype B) KS b-galactosidase None
MPS VI (Maroteaux-Lamy disease) DS N-acetylgalactosamine 4-
sulfatase
None
MPS VII (Sly disease) DS, HS b-glucuronidase Usually mild
MPS IX Hyaluronan Hyaluronidase Noneb
a Abbreviations: DS – dermatan sulfate, HS – heparan sulfate, KS – keratan sulfate.
b Only one patient has been described to date, thus, this case is non-conclusive for occurrence of neurological symptoms in this disease.
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As shown in Table 1, most patients suffering from MPS I (Hurler
disease), MPS II (Hunter diseases) and MPS VII (Sly diseases), and
all patients suffering from MPS III (Sanﬁlippo disease) develop
CNS pathology, which results not only in neurological symptoms
but also in severe cognitive and behavioral disturbances. Among
neurological problems of MPS patients, vision and hearing prob-
lems, epilepsy and various seizures may be recognized as predom-
inant symptoms [1]. However, apart from such symptoms,
neuronopathic forms of MPS are characterized by severe behav-
ioral disturbances and loosing of cognitive skills [4–6]. In this pa-
per we will focus on these behavioral disturbances as they are
considerably different in various MPS types.Various behaviors in different MPS types
Although loosing of cognitive skills is common in vast majority
of neuronopathic MPS patients, there are obvious differences be-
tween behaviors of children affected with various MPS types. In
MPS I patients with neuronopathy, despite problems with learning
and cognitive deterioration, little or no behavioral problems occur
[1,5]. Such a clinical picture is also common for MPS VII patients
[1]. On the other hand, MPS II patients, and particularly MPS III pa-
tients (all subtypes), develop an aggressive behavior in the course
of the disease [4–6]. MPS II children are often overactive, but this
symptom is especially severe in MPS III patients, which are usually
described as hyperactive. These patients have usually severe sleep-
ing defects, and can sleep only a couple of hours a day. MPS II and
MPS III children may become unexpectedly angry or may laugh
without any reason. Contrary to them, MPS I and MPS VII patients
are generally placid, gentle and calm, even if cognitive deteriora-
tion is severe. Furthermore, MPS I children are often over-careful,
while MPS III patients appear to ignore any danger, and their
behavior suggests intensive action without any particular sense,
often leading to body injuries due to running into potentially dan-
gerous environment.
These different behaviors, characteristic for particular MPS
types and discussed in various review articles [1,4–6], are summa-
rized in Table 2. Although these behaviors are clinically clearly rec-
ognized, the reason of such huge differences between patients
accumulating the same storage material, HS, is unclear.Potential biochemical reasons of various behaviors among
patients suffering from different MPS types
As it is evident from Tables 1 and 2, all neurological symptoms
and behavioral disturbances which occur in MPS patients correlate
with storage of HS. However, variety of behavioral problems char-
acteristic for particular MPS types is surprising. One extreme is
behavior of MPS I and MPS VII patients, which is generally normal
and the affected children are usually placid, gentle and calm. An-
other extreme is behavior of MPS III patients, i.e. their hyperactiv-
ity, aggressive behavior and sleepless. Behavior of MPS II patients
can be classiﬁed as intermediate, between these two extremes.
The above described differences cannot be explained on the ba-
sis of the old hypothesis on the mechanism of lysosomal storage
diseases, which assumed that a storage of an undegraded material
in lysosomes is the only cause of clinical symptoms. If this was the
case, storage of various partially degraded HS derivatives should
cause similar symptoms, which is clearly not true. More recent
concept of the mechanism of neuropathology in MPS patients arose
from the fact that there are secondary storage products, found in
brains of both animal models and patients suffering from
MPS, especially gangliosides GM2 (II3-N–acetylneuraminosyl-
gangliotriaosylceramide) and GM3 (II3-N–acetylneuraminosyllac-
tosylceramide), which are believed to be responsible for neuro-
degeneration in some other lysosomal storage diseases [7–16].
This secondary storage could be caused by GAG-mediated inhibi-
tion of activities of lysosomal enzymes involved in ganglioside deg-
radation [17–19]. Interestingly, the presence of accumulated GM2
and GM3 gangliosides correlated with neuropathology in MPS.
Therefore, as discussed recently [20], it was proposed that these
secondary storage materials, rather than primarily stored GAGs,
might be responsible for neuronopathy in MPS patients. However,
GAGs and gangliosides were found to be localized differentially in
MPS cells [13]. Moreover, accumulation of gangliosides was also
observed in lysosomal storage diseases without either defects in
enzymes involved directly in their degradation or know GAG stor-
age [21]. Therefore, it was concluded that these results raise signif-
icant questions about whether GAG-induced inhibition of
lysosomal enzymes occurs in vivo, and whether it is a mechanism
underlying GM2 and GM3 storage in MPS [20]. Although these
questions do not exclude a role for gangliosides in development
of neuropathology during the course of MPS diseases, the second-
ary storage of these compounds deﬁnitely cannot explain the dif-
Table 2
Behavioral disturbances in various types of MPS.
MPS
type
Characteristic behavior Additional (apart from those common for all carbohydrates) chemical moieties
at the ends of partially degraded HS
MPS I Little or no behavioral problems; placid and calm behavior; sometimes
over-careful behavior
None
MPS II Aggressive behavior; overactivity; anger or laugh without a reason Sulfate (bound directly to the carbohydrate backbone)
MPS III
(A–D)
Aggressive behavior; hyperactivity; sleep disturbance; anger or laugh
without a reason; no care on danger
N-sulfate, amino, N-acetyl
MPS VII Little or no behavioral problems; placid and calm behavior None
Fig. 1. The pathway of HS degradation. Particular degradation steps, marked by
numbers, are catalyzed by enzymes whose deﬁciencies result in certain MPS types,
shown in frames (a disease caused by deﬁciency of glucuronate sulfatase is not
known, and is described as a question mark). The enzymes catalyzing particular
reactions are as follows: 1 – iduronate sulfatase, 2 – a-L-iduronidase, 3 – heparan N-
sulfatase, 4 – acetyl-CoA:a-glycosaminide acetyltransferase, 5 – a-N-actylglucosa-
minidase, 6 – glucuronate sulfatase, 7 – b-glucuronidase, 8 – N-acetylglucosamine
6-sulfatase. The ‘circled S’ indicates the sulfate moiety. The scheme is based on the
review by Neufeld and Muenzer [1], and was modiﬁed.
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Namely, the same kinds of gangliosides accumulate in all neuron-
opathic forms of MPS diseases [20], while behaviors of patients are
considerably different.
It became more and more obvious that undegraded or partially
degraded GAGs are not only stored in lysosomes, but they can also
accumulate outside these organelles, and outside cells. As demon-
strated recently, in a culture of human ﬁbroblasts derived from an
MPS patient, in the presence of factors allowing effective synthesis
of GAGs, there are so many lysosomes fulﬁlled with the storage
material, that some of them can be damaged or even ‘‘excreted”
outside the cell [22]. It is likely that in vivo, the material from ex-
creted and damaged lysosomes may then accumulate in the extra-
cellular matrix and can interfere with reactions between cells. If
this occurs in the brain, transmission of signals between neurons
can be inﬂuenced by reactive small molecules or chemical moieties
of larger molecules.
In the light of the assumption described above, it is necessary to
consider the biochemical pathway of HS degradation. It is worth
noting that this degradation proceeds gradually, by removing par-
ticular chemical moieties or monosaccharides, step by step. This
degradation pathway, established on the basis of biochemical anal-
yses performed in vitro, is depicted in Fig. 1. Inability to remove the
sulfate moiety, due to deﬁciency of iduronate sulfatase, causes a
block in further degradation of HS, and results in MPS II. A lack
of a-L-iduronidase activity causes MPS I, as iduronate cannot be re-
moved from the end of the HS polysaccharide chain. Deﬁciency in
next three enzymes in this pathway results in inhibition of HS deg-
radation at subsequent steps, and is a cause of symptoms charac-
teristic for MPS IIIA, C and B, respectively. In fact, clinical
symptoms of all four MPS III subtypes (A–D) are similar, and thus,
these disorders are grouped in the one type of MPS (type III), called
also Sanﬁlippo disease. It is interesting that a disease caused by
deﬁciency in activity of the next enzyme in the HS degradation
pathway, glucuronate sulfatase, is not known. Despite this, a lack
of the b-glucuronidase causes MPS VII, and N–actylglucosamine
6-sulfatase deﬁciency results in symptoms of MPS IIID.
Importantly, speciﬁc biochemical markers, occurring in urine of
patients, characteristic for particular MPS types and subtypes, were
identiﬁed [23]. These markers consisted of oligosaccharides, which
have a non-reducing terminus identical to the speciﬁc substrate for
the deﬁcient enzyme in the particular MPS disease. For example,
di- and tri-saccharides characteristic for MPS I (the disease caused
by deﬁciency of a-L-iduronidase) contained a-L-iduronic acid at the
non-reducing end, oligosaccharides speciﬁc for MPS II (the disease
caused by deﬁciency in iduronate sulfatase) did bear the sulfate on
the terminal non-reducing a-L-iduronic acid, and so on [23]. These
results provided a proof that theoretically predicted (on the basis
of biochemical analyses performed in vitro) products of incomplete
degradation of GAGs occur in bodies of MPS patients, indeed. Most
probably, the oligosaccharides detected experimentally in urine
samples of patients arose from endolytic cleavage of larger GAG
fragments followed by exolytic trimming to the resistant (due to
a lack of particular enzymes) structures. From the point of view
of mechanisms of neuronopathy in MPS diseases, another discov-ery appears to be crucial. Namely, levels of di- and tri-saccharides
characteristic for MPS I correlated with the presence/absence of
CNS pathology in patients [24]. These results strongly suggest that
chemical products of incomplete HS degradation, which occur
in vivo, are responsible (either directly or indirectly) for develop-
ment of CNS problems (including behavioral ones) in MPS patients.
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tial biochemical mechanism of differences in behaviors of patients
suffering from various MPS types, one should ask a question
whether it is possible to ﬁnd any chemical features which are com-
mon for three groups of behavioral schemes, characteristic for: (i)
MPS I and MPS VII, (ii) MPS III (A–D), and (iii) MPS II. Interestingly,
in bodies of MPS patients who express little or no behavioral dis-
turbances, i.e. MPS I and MPS VII patients, there is an accumulation
of intermediates of HS degradation which contain no additional
(i.e. apart from those which are sugar-speciﬁc –OH and –H) chem-
ical moieties at the non-reducing terminus (Fig. 1 and Table 2). On
the other hand, MPS III correlates with storage of partially de-
graded HS molecules containing, at the non-reducing terminal
monosaccharide, either N-sulfate (MPS IIIA), amino (MPS IIIC) or
N-acetyl (MPS IIIB and MPS IIID) moiety. MPS II patients, with
the intermediate behavior, accumulate the compound bearing
the sulfate moiety at the non-reducing terminal monosaccharide,
which is, contrary to MPS IIIA, O-bonded rather than N-bonded.
On the basis of the above analysis, we suggest that the presence
of the partially degraded HS with sulfate or acetyl moiety bonded
to the sugar backbone through the N atom, or only the amino moi-
ety, at the non-reducing terminus, causes behavioral symptoms
characteristic for MPS III. We speculate that this might be due to
reactivity of these N-containing moieties. Moreover, if sulfate moi-
ety is O-bonded to the non-reducing terminal monosaccharide of
HS degradation intermediate, the MPS II-like behavior occurs.
Finally, no additional chemical moieties at the non-reducing termi-
nus of partially degraded HS results in no behavioral disturbances,
as observed in MPS I and MPS VII patients. If this hypothesis were
true, putative patients suffering from a currently unknown disease
caused by deﬁciency in glucuronate sulfatase should develop a
behavior similar to that described for MPS II (compare Fig. 1 and
Table 2).
The above presented proposal is hypothetical, however, it opens
clear ways to its experimental testing. Namely, if this hypothesis is
true, behaviors of experimental animals whose brains were in-
jected with either synthetic monosaccharides corresponding to
non-reducing terminal sugars occurring in particular MPS types
or oligosaccharides characteristic for particular MPS types and
identiﬁed previously [23], should be similar to behaviors charac-
teristic for MPS I, MPS II, MPS III and MPS VII patients. Moreover,
such behaviors should correspond to those occurring in animal
models of these diseases. It is worth mentioning that such models
of MPS I, MPS II, MPS IIIA, MPS IIIB and MPS VII are already avail-
able [25–32].
Finally, if the presented hypothesis were true, it might shed a
new light on biochemical mechanisms of behavioral disturbances
found not only in MPS but also in other diseases. Namely, speciﬁc
chemical moieties might inﬂuence particular reactions occurring in
brain during transmission of signals between neurons. In fact,
although direct molecular reasons for abnormal behaviors of af-
fected patients remain to be elucidated, it was indicated recently
that results of studies on neuronopathic MPS and other LSD may
be very important to understand pathomechanisms of many other
neurodegenerative disorders, including Alzheimer disease, Parkin-
son disease and Huntington disease [33].Conﬂicts of interest statement
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